Our Mission
Monopar Therapeutics strives to develop proprietary therapeutics designed to extend life or improve the quality of life for cancer patients
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates.
Monopar's team is located in San Francisco, CA and Chicago, IL.
Licensing, developing and commercializing transformative oncology therapeutics
Multiple factors drive our passion for oncology
The numbers behind our research define camsirubicin opportunities
Monopar’s pipeline consists of camsirubicin, a proprietary analog of doxorubicin for the treatment of advanced soft tissue sarcoma, engineered specifically to minimize toxic effects on the heart while retaining anticancer activity; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Product | Indications | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
---|---|---|---|---|---|---|
Camsirubicin |
Advanced Soft Tissue Sarcoma |
Preclinical complete |
Phase 1 in progress |
Phase 2 not started |
Phase 3 not started |
Phase 1b trial ongoing in the US |
MNPR-101 RIT |
Advanced Solid Cancers |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Collaboration with NorthStar, late preclinical |
MNPR-101-Zr |
Imaging Agent for RIT |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Collaboration with NorthStar, late preclinical |
MNPR-202 |
Advanced Solid Cancers |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Early preclinical |